Pressure BioSciences, Inc. (PBIO) Corporate Media Kit

Key Achievements To Date: 2017 SHORT-TERM GROWTH DRIVERS • Research Products & Services (PCT Platform): Consistent Revenue Stream from Sales of Instruments (Barocycler 2320EXT, Barozyme, HUB) and Consumables to Academic, Government, Biopharma, and Biotechnology Companies Worldwide. New Focus (2019) on Improved Characterization and Quality Control of Protein Therapeutics for the Biopharma Market. Continued Focus on High Quality Sample Preparation for Biomarker and Target Discovery, Pathology, and Movement Down the Path to Clinical Diagnostics. • Biopharma Contract Services (BaroFold Platform): Consistent Revenue Stream from Offering Disaggregation and Controlled Refolding Services to Protein Therapeutic Companies, plus the Potential for Millions of $$ from Royalties through Manufacturing Scale Licenses. • Nanoemulsion Manufacturing Services (UST Platform): Consistent Revenue Stream from Sales of UST-Based, Proprietary Instrumentation and Consumables for Processing Oil-based Solutions into Stable, Water-Soluble Nanoemulsions. Initial Focus (2019/2020) on Cannabis (CBD) Companies. Beginning in 2021, Focus will Expand to Include the non-Cannabis Nutraceuticals Industry, as well as the Cosmetics and Food & Beverage Industries. 37